Observational cohort of patients with spondyloarthritis at Nanfang Hospital
Official title: Bidirectional Cohort Study of Nanfang Spondyloarthritis
Run by Nanfang Hospital, Southern Medical University · NCT06988813 · Data updated 2026-11-12
This study is collecting health information from patients with spondyloarthritis at Nanfang Hospital to better understand the condition over time without changing their usual care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 10 Years to 59 Years |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Nanfang Hospital, Southern Medical University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | May 17, 2025 |
| Main results expected | April 30, 2030 |
| Study ends | April 30, 2030 |
| Registry record updated | May 25, 2025 |
| Trial ID | NCT06988813 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 10 to 59 years with a standardized diagnosis of spondyloarthritis who have attended Nanfang Hospital between 2010 and 2025.
✕Probably not a fit
Patients who are pregnant, preparing for pregnancy, breastfeeding, or have moderate to severe heart failure will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to establish a specialized cohort of spondyloarthritis (SpA) patients at Nanfang Hospital, where clinical condition scales, laboratory indicators, and imaging data will be collected during routine follow-up visits. The cohort will archive disease characteristics, biochemical index data, and disease assessment scales without imposing any interventional treatments or additional tests on patients. Data will include disease duration, symptom characteristics, comorbidities, and various imaging results, creating a comprehensive dataset for future analysis of SpA. The study will span from 2010 to 2030, capturing both prospective and retrospective data.
Why it matters
Potential benefit: If successful, this study could enhance understanding of spondyloarthritis and improve patient management through comprehensive data collection.
How similar studies have gone: While this approach is observational and builds on existing methodologies, similar studies have shown success in establishing disease cohorts for chronic conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1.Attended Nanfang Hospital, Southern Medical University, 2010-2030 2.Prospective cohort study component: subjects voluntarily participate with informed consent and sign an informed consent form 3.Retrospective cohort study: (i) patients who visited the hospital from April 2010 to April 2024 (and who will not return to the hospital at a later date) were exempted from informed consent; (ii) patients who visited the hospital from May 2024 to April 2025 were required to sign an informed consent 4.10 years old ≤ age ≤ 59 years old 5.Patients with a standardized diagnosis of spondyloarthritis by the following guidelines or diagnostic criteria, i.e., meeting one of the following diagnostic criteria: (1) 2009 ASAS classification criteria for axial spondyloarthritis; (2) 2011 ASAS classification criteria for peripheral spondyloarthritis Exclusion Criteria: * 1\. Women who are pregnant, preparing for pregnancy or breastfeeding 2.Moderate to Severe Heart Failure (New York Heart Association Class 3-4) 3.Active peptic ulcers/bleeding 4.Judged by the investigator to be unsuitable for participation in this study
Where it's running
-
Nanfang Hostipal,Southern Medical University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Jun Xiao, Dr
- Email: orthopaedxj@163.com
- Phone: 0086-20-18665000156
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Benzathine penicillin plus etanercept for spondyloarthritis
This trial will test whether adding benzathine penicillin to etanercept helps adults with spondyloarthritis reduce disease activity more than etanercept alone.
-
MST-931 in healthy adults
This early-phase study tests a single subcutaneous dose of MST-931 to see if it is safe and how it behaves in the body in healthy adults.
-
Validation of the 2025 Axial Spondyloarthritis Classification Criteria in Chinese patients
This study tests whether the 2025 ASAS-SPARTAN criteria correctly classify axial spondyloarthritis in adults with chronic back pain in China.
-
ESPB for persistent back pain in ankylosing spondylitis
This trial tests whether an erector spinae plane block can help reduce persistent back pain in adults with ankylosing spondylitis who still have pain despite controlled disease activity.
-
Effect of smartphone use on neck posture and function in RA/AS patients and healthy controls
This study tests how smartphone use relates to neck posture, tongue pressure, balance, and neck-related disability in people with rheumatoid arthritis or ankylosing spondylitis compared with healthy individuals.
-
Combining Traditional Chinese and Western medicine to improve function in ankylosing spondylitis
We will test whether combining Traditional Chinese and Western medicine improves how well adults with ankylosing spondylitis can function after six months.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.